In addition to the findings presented here for AD, NRG1 signaling has been shown to be pathogenic in models of chronic pain (Calvo et al., 2010, 2011), multiple sclerosis (Allender et al., 2018), and ALS (Song et al., 2012, 2014; Liu et al., 2018; Schram et al., 2020). Here, NRG1 is linked to multiple sclerosis.